Quarter Ending 12-31-2010: 26,489,904 shares.
Quarter Ending 12-31-2011: 44,117,044 shares.
Quarter Ending 12-31-2014: 70,494,863 shares.
All figures are from the 10-Q's found on the SEC website. If you really want to see some interesting numbers, look at the report dated 2-9-2011. There you will find charts listing the shares from as far back as 2003, when, at the end of June, there were only 109,655 shares and Quarter Ending 6-30-2007 amounted to 4,954,110 shares after the secondary of 3,126,177 shares.
The new report will be out in a few days. watch for it because Zami won't tell you when nor will he ever host a CC. History shows on the 8th, but this year it's a Friday. Expect them the 7th or 11th. keep an eye on the cash, it will be closing in around $35M. That equates to about 6 quarters provided the burn rate doesn't increase.
However, as they intend to start new trials this year (so says Zami's lip service) it's highly plausible more cash will flow out the door and quite predictable dilution isn't that far off.
Allo: These are the facts, Jack.
From the Wainwright report dated 2/18/15.
"Clinical Development of PLX-PAD
1. Based on our conversation with management, the randomized, double-blind, placebo-controlled Phase 2 trial in IC has enrolled more than 60 patients at 23 sites in the US, Germany, Israel, and South Korea, and targets to enroll a total of 150 patients."
From the Wainwright report dated 11/11/14:
"Clinical Development of PLX-PAD
1. Based on our conversation with management, the randomized, double-blind, placebo-controlled Phase 2 trial in IC has enrolled approximately 60 patients at 19 sites in the US, Germany, Israel, and South Korea, and targets to enroll an additional 90."
It doesn't seem to be progressing very rapidly.
Pluristem first needs to complete enrollment in the IC trial. 3 years and less than half fulfilled. Why is that?
According to one of the most recent analyst reports, they will have ~$31M at the end of the current quarter. That should give a hint as to what will happen with the shelf.
In response to your post below kgjie, yes, they have a vote every year. Last year. Zami received more "nay" votes than any other board member. Around 2.5-3M (15-20%) from memory but you can check the SEC website for the exact amount. Unfortunately, there are no major shareholders to vote him out. He's a disastrous CEO and his lackey Yaki could go as well. Cronies from a previous company, two peas in a pod. No good.
Words from a previous buteao post: "I look forward to the many advances in the field no matter where it comes from! And I will be the first from now-on to say congratulations and Godspeed to your Company! We start a new Day Now! Buteo who now goes by: allo.geneic"
Management didn't follow through on their hype. All these Asian conferences and no deals. They continue to distract their investors by issuing more statements about their "plans" and "pursuits" but with no execution. As the old adage goes: "The road to he** is paved with good intentions."
Because the frauds can't remove your post, they will then apply the tactic of incessant posting in an attempt to bury anything and everything.
It makes me wonder why people put their faith in this fraud.
Never post a negative thought below any of allo's messages. It's a guarantee allo will remove his post resulting in any subsequent replies also disappearing from the thread.
I find myself viewing the "Messages" list as opposed to the "Topics" list these days. The fraud can't remove your posts completely.
A childish imp the allo is.
Once again, the only ongoing trial in South Korea is the PH2 IC trial. As of February 18, 2015, a little over 60 patients have been enrolled worldwide. Read the Wainwright report. There is no data from this trial.
The trading range is gradually moving up as you have commented before. A good sign. Let's look at the forthcoming catalysts. My guess is the CLI trial would be the first. This could happen at any time. When it does, there will be a partnership announcement. I would presume it would be in Asia. As noted in the Wainwright report, they don't plan on going at this alone.
The second catalyst may be a little further out. This is the completion if the IC trial enrollment. Unfortunately, this has been a long, slow ride and hopefully the new centers will aid in their efforts. I still think this is at least 6 months away.
Thirdly, is the United trial in Australia. Again, this seems to be dragging a bit too long, but, we can still expect some data later this year.
Finally, we have ARS. This is probably the furthest out as there still is a trial design and more animal trials to be completed. The good news here is that the NIH is willing to continue to investigate this indication.
Let's hope management can execute.
This is where we stand. A little better off than six months ago. Now we can begin to see some speculators coming on board. In the meantime, it's safe to say hold your shares and perhaps pick up a couple extra on a dip for trading.
On another note, keep an eye on their cash. It's dipping down below $40M.
Honestly, I don't believe angel and the fraud are one and the same. Angel is suffering from 8 years of losses and is bitter. The fraud is just full of themselves.
Always be sure to hit the "After Hours Quote" link on the left. All the details are there. Also, you can scroll over the chart.